Cipher Pharmaceuticals Stock Shares Owned By Institutions
| CPHRFDelisted Stock | USD 2.57 0.00 0.00% |
Cipher Pharmaceuticals fundamentals help investors to digest information that contributes to Cipher Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Cipher OTC Stock. The fundamental analysis module provides a way to measure Cipher Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cipher Pharmaceuticals otc stock.
Cipher |
Cipher Pharmaceuticals OTC Stock Shares Owned By Institutions Analysis
Cipher Pharmaceuticals' Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
More About Shares Owned By Institutions | All Equity Analysis
Shares Held by Institutions | = | Funds and Banks | + | Firms |
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
CompetitionBased on the latest financial disclosure, 0.0% of Cipher Pharmaceuticals are shares owned by institutions. This is 100.0% lower than that of the Pharmaceuticals sector and about the same as Health Care (which currently averages 0.0) industry. The shares owned by institutions for all United States stocks is 100.0% higher than that of the company.
Cipher Shares Owned By Institutions Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cipher Pharmaceuticals' direct or indirect competition against its Shares Owned By Institutions to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Cipher Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Cipher Pharmaceuticals by comparing valuation metrics of similar companies.Cipher Pharmaceuticals is currently under evaluation in shares owned by institutions category among its peers.
Cipher Fundamentals
| Return On Equity | 0.24 | ||||
| Return On Asset | 0.15 | ||||
| Profit Margin | 0.45 % | ||||
| Operating Margin | 0.57 % | ||||
| Current Valuation | 46.13 M | ||||
| Shares Outstanding | 25.12 M | ||||
| Shares Owned By Insiders | 44.12 % | ||||
| Number Of Shares Shorted | 11.43 K | ||||
| Price To Earning | 15.54 X | ||||
| Price To Book | 1.63 X | ||||
| Price To Sales | 3.28 X | ||||
| Revenue | 21.94 M | ||||
| Gross Profit | 18.26 M | ||||
| EBITDA | 11.85 M | ||||
| Net Income | 7.76 M | ||||
| Cash And Equivalents | 24.19 M | ||||
| Cash Per Share | 0.96 X | ||||
| Total Debt | 507 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 2.51 X | ||||
| Book Value Per Share | 1.77 X | ||||
| Cash Flow From Operations | 13.81 M | ||||
| Short Ratio | 0.97 X | ||||
| Earnings Per Share | 0.36 X | ||||
| Target Price | 5.59 | ||||
| Number Of Employees | 26 | ||||
| Beta | 1.03 | ||||
| Market Capitalization | 64.32 M | ||||
| Total Asset | 51.65 M | ||||
| Z Score | 75.6 | ||||
| Net Asset | 51.65 M |
About Cipher Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cipher Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cipher Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cipher Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Other Consideration for investing in Cipher OTC Stock
If you are still planning to invest in Cipher Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Cipher Pharmaceuticals' history and understand the potential risks before investing.
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |